A Real-World Study of Diffuse Large B-Cell Lymphoma (DLBCL) Patients With Different Genetic Subtypes
Status: Recruiting
Location: See location...
Intervention Type: Other
Study Type: Observational
SUMMARY
To collect and evaluate the data of real-world treatment regimen, efficacy, safety and survival information of DLBCL patients with different genetic suptypes
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:
• Histologically-confirmed diffuse large B-cell lymphoma (DLBCL)
• Genetic subtype belonging to at least one of the seven subtypes by using next generation sequencing: MCD, BN2, N1, ST2, A53, EZB (MYC+, MYC-) and others
• Fully comprehension and signature of the informed consent form (ICF) for participation
Locations
Other Locations
China
Ruijin Hospital, Shanghai Jiao Tong University School of Medicine
RECRUITING
Shanghai
Contact Information
Primary
Weili Zhao
zwl_trial@163.com
+862164370045
Backup
Pengpeng Xu
pengpeng_xu@126.com
+862164370045
Time Frame
Start Date: 2023-10-01
Estimated Completion Date: 2026-12-31
Participants
Target number of participants: 10000
Treatments
All enrolled patients
All patient who signed the consent form for participation to the study
Related Therapeutic Areas
Sponsors
Leads: Ruijin Hospital